The downgrade by Barclays from Overweight to Equal-Weight suggests a neutral outlook on Corteva's stock, indicating that the stock may perform in line with the market. The reduction in price target from $66 to $50 represents a significant decrease in expected value, which could lead to a negative short-term impact on the stock price as investors adjust their expectations.